Table 6.
Risk of asthma exacerbation in ACO and pure asthma group according to biologics type (N = 87).
| Adjusted model | Reference |
Mepolizumab & Reslizumab (n = 60) |
Dupilumab (n = 27) |
||||
|---|---|---|---|---|---|---|---|
| Pure asthma |
ACO |
p-value | ACO |
p-value | |||
| OR | 95 % CI | OR | 95 % CI | ||||
| Model 1: no adjustment | 1.0 | 0.8 | 0.1, 7.9 | 0.854 | 5.3 | 0.8, 34.1 | 0.077 |
| Model 2: age, sex, BMI adjusted | 1.0 | 1.1 | 0.1, 13.1 | 0.919 | 3.5 | 0.5, 26.4 | 0.231 |
| Model 3: age, sex, BMI + smoking pack-year | 1.0 | 0.9 | 0.1, 13.6 | 0.924 | 1.6 | 0.1, 18.8 | 0.716 |
| Model 4: Model 3 + blood eosinophils | 1.0 | 0.9 | 0.1, 13.5 | 0.917 | 1.4 | 0.1, 17.1 | 0.806 |
| Model 5: Model 3 + FeNO | 1.0 | 1.1 | 0.1, 17.3 | 0.958 | 2.1 | 0.1, 33.6 | 0.615 |
| Model 6: Model 3 + blood eosinophils, FeNO | 1.0 | 1.1 | 0.1, 17.7 | 0.948 | 1.6 | 0.1, 27.7 | 0.765 |
| Model 7: Model 3 + blood eosinophils, FeNO, number of exacerbations at baseline | 1.0 | 0.9 | 0.1, 15.4 | 0.931 | 2.2 | 0.1, 50.1 | 0.634 |
All adjusting variables were measured at baseline visit. Abbreviations: ACO, Asthma-COPD Overlap; OR, odds ratio; CI, confidence interval; BMI, body mass index; FeNO, fractional exhaled nitric oxide.